Detail

Study ID: NRG GY009

Title:

A RANDOMIZED, PHASE II/III STUDY OF PEGYLATED LIPOSOMAL DOXORUBICIN AND CTEP-SUPPLIED ATEZOLIZUMAB (IND #134427) VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN, CTEP-SUPPLIED BEVACIZUMAB AND CTEP-SUPPLIED ATEZOLIZUMAB VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN AND CTEP-SUPPLIED BEVACIZUMAB IN PLATINUM RESISTANT OVARIAN CANCER

Location:
Bemidji Clinic, Bismarck Region, Fargo Region, Sioux Falls Region
Principal Investigator:
Maria Bell, MD
Disease:
Ovary/Fallopian Tube/Primary Peritoneal
Stage:
Phase II/III
Status:
Active - Open to Accrual